Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Roche 1H11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Roche 1H11

Group sales were stable in local currencies, up 2%.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche 1H11*

YTD Revenues: 21.7 billion (-12%)

YTD Earnings: 5.3 billion (-5%)

Comments: Group sales, excluding Tamiflu, were up 2% in local currencies to 21.4 billion. Pharmaceutical sales were down 11% to 16.8 billion (-1% in LC). The decrease in Avastin and Tamiflu sales, generic competition for CellCept, and competition for the NeoRecormon/Epogin franchise, was partially offset by continued growth of Herceptin, MabThera/Rituxan, Xeloda and Tarceva, Lucentis and Actemra/RoActemra. R&D costs were down 11% to 3.9 billion. Diagnostics Division sales fell 8% to 4.9 billion (+5% LC)

*All numbers reported in CHF

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters